A Cloning Emergency in Britain?

Since the beginning of 2001--Jan. 22 to be exact--it seemed that one country, the United Kingdom, had unambiguously--and literally--gotten its act together on cloning. On that day the House of Lords passed regulations, adopted by the House of Commons one month before, that not only allowed embryonic stem cell research to develop therapies for devastating and intractable diseases, but also situated cloning squarely within the framework of the Human Fertilisation and Embryology Act of 1990. Or so

Written byArlene Judith Klotzko
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

In a challenge to the regulations brought by the Pro-Life Alliance, a High Court judge had to decide whether the definition of an embryo, written into the 1990 act, could embrace an embryo produced by nuclear transfer. He said no. Thus, none of the provisions in the act could be applied to cloned embryos. In one judicial stroke, the basis for allowing therapeutic cloning and the mechanism for prohibiting reproductive cloning simply vanished. Stem cell research remained unaffected, as long as the embryos used are products of fertilization.

The government responded immediately, announcing its appeal and also whipping up, in record time, "emergency legislation" that would ban reproductive cloning and make it a criminal offense. Indeed, four days after the court decision--almost 10 months to the day after the House of Lords debate and vote--I found myself back in the chamber listening to many of the same arguments made by ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies